🇺🇸 Fourth of July Sale! Save 25%
Free Express Shipping
Sale Ends: 07/08
Uses
Side effects
Interactions
Precautions
How Abilify Works
- ABILIFY is an atypical antipsychotic. The oral formulations are indicated for: Schizophrenia, Acute Treatment of Manic, and Mixed Episodes associated with Bipolar I. Adjunctive Treatment of Major Depressive Disorder. Irritability Associated with Autistic Disorder, Treatment of Tourette’s disorder the injection is indicated for: Agitation associated with schizophrenia or bipolar mania.
- Adult patients with schizophrenia: akathisia
- Pediatric patients (13 to 17 years) with schizophrenia: extrapyramidal disorder, somnolence, and tremor
- Adult patients (monotherapy) with bipolar mania: akathisia, sedation, restlessness, tremor, and extrapyramidal disorder
- Adult patients (adjunctive therapy with lithium or valproate) with bipolar mania: akathisia, insomnia, and extrapyramidal disorder
- Pediatric patients (10 to 17 years) with bipolar mania: somnolence, extrapyramidal disorder, fatigue, nausea, akathisia, blurred vision, salivary hypersecretion, and dizziness
- Adult patients with major depressive disorder (adjunctive treatment to antidepressant therapy): akathisia, restlessness, insomnia, constipation, fatigue, and blurred vision
- Pediatric patients (6 to 17 years) with autistic disorder: sedation, fatigue, vomiting, somnolence, tremor, pyrexia, drooling, decreased appetite, salivary hypersecretion, extrapyramidal disorder, and lethargy
- Pediatric patients (6 to 18 years) with Tourette’s disorder: sedation, somnolence, nausea, headache, nasopharyngitis, fatigue, increased appetite Adult patients with agitation associated with schizophrenia or bipolar mania: nausea
- Factors Dosage Adjustments for ABILIFY
- Known CYP2D6 Poor Metabolizers Administer half of usual dose
- Known CYP2D6 Poor Metabolizers and strong CYP3A4 inhibitors Administer a quarter of usual dose
- Strong CYP2D6 or CYP3A4 inhibitors Administer half of usual dose
- Strong CYP2D6 and CYP3A4 inhibitors Administer a quarter of usual dose
- Strong CYP3A4 inducers Double usual dose over 1 to 2 weeks
- Neuroleptic Malignant Syndrome: Manage with immediate discontinuation
and close monitoring - Tardive Dyskinesia: Discontinue if clinically appropriate
- Metabolic Changes: Atypical antipsychotic drugs have been associated with
metabolic changes that include hyperglycemia/diabetes mellitus,
dyslipidemia, and body weight gain - Hyperglycemia/Diabetes Mellitus: Monitor glucose regularly in
patients with and at risk for diabetes - Dyslipidemia: Undesirable alterations in lipid levels have been
observed in patients treated with atypical antipsychotics - Weight Gain: Weight gain has been observed with atypical
antipsychotic use. Monitor weight - Orthostatic Hypotension: Monitor heart rate and blood pressure and warn
patients with known cardiovascular or cerebrovascular disease, and risk of
dehydration or syncope - Leukopenia, Neutropenia, and Agranulocytosis: have been reported with
antipsychotics including ABILIFY. Patients with a history of a clinically
significant low white blood cell count (WBC) or a drug-induced
leukopenia/neutropenia should have their complete blood count (CBC)
monitored frequently during the first few months of therapy and
discontinuation of ABILIFY should be considered at the first sign of a
clinically significant decline in WBC in the absence of other causative
factors - Seizures/Convulsions: Use cautiously in patients with a history of seizures or
with conditions that lower the seizure threshold - Potential for Cognitive and Motor Impairment: Use caution when operating
machinery - Suicide: The possibility of a suicide attempt is inherent in schizophrenia and
bipolar disorder. Closely supervise high-risk patients
